[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Lactose Intolerance - Pipeline Insight, 2019

August 2019 | 60 pages | ID: L4A2A0A2968EN
DelveInsight

US$ 1,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 24 Hours

"Lactose Intolerance - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lactose Intolerance pipeline landscape is provided which includes the disease overview and Lactose Intolerance treatment guidelines. The assessment part of the report embraces, in depth Lactose Intolerance commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lactose Intolerance collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Lactose Intolerance Understanding

Lactose Intolerance (LI) is defined as a clinical syndrome characterized by pain and abdominal distention, flatulence, and diarrhea that occurs after lactose consumption. These symptoms—produced by malabsorption of lactose, a sugar found in milk and other dairy products—often result in avoidance of dairy products by afflicted individuals. Lactose malabsorption occurs because of a decreased ability to digest lactose, due to a deficiency in the levels of the enzyme lactase. Lactase breaks lactose down into two simpler sugars, glucose and galactose, which are readily absorbed into the bloodstream. This enzyme is produced by expression of the lactase-phlorizin hydrolase gene in the cells lining the small intestine. Lactose intolerance is mainly caused by genome-diet interaction and depends not only on the expression of lactase enzyme but also on the dose of lactose intake, intestinal flora, gastrointestinal motility, small intestinal bacterial overgrowth. Along with this, the sensitivity of the gastrointestinal tract to generate gas and other fermentation products due to lactose digestion. There are several factors that influence the lactose intolerance that may include Hypolactasia, Lactase non-persistence, Lactase persistence, Lactose maldigestion, lactose malabsorption, and Lactose malassimilation.

Lactose Intolerance Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Lactose Intolerance targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Lactose Intolerance pipeline report covers 3+ companies. Some of the key players include Ritter Pharmaceuticals (RP-G28) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Lactose Intolerance Analytical Perspective by DelveInsight
  • In-depth Lactose Intolerance Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Lactose Intolerance Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Lactose Intolerance report provides an overview of therapeutic pipeline activity for Lactose Intolerance across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Lactose Intolerance therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Lactose Intolerance Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Lactose Intolerance
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Lactose Intolerance to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Lactose Intolerance R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Lactose Intolerance in licensing and out licensing strategies by identifying prospective partners with progressing projects for Lactose Intolerance to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. LACTOSE INTOLERANCE

2.1. Lactose Intolerance Disease Overview
2.2. Lactose Intolerance History
2.3. Lactose Intolerance Symptoms
2.4. Lactose Intolerance Causes
2.5. Lactose Intolerance Pathophysiology
2.6. Lactose Intolerance Diagnosis
  2.6.1. Diagnostic Guidelines

3. LACTOSE INTOLERANCE CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. LACTOSE INTOLERANCE - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Lactose Intolerance companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Lactose Intolerance Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Lactose Intolerance Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. LACTOSE INTOLERANCE PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. LACTOSE INTOLERANCE -PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. RP-G28- Ritter Pharmaceuticals
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table
To be continued in the report…………………………

7. RECENT TECHNOLOGIES

8. LACTOSE INTOLERANCE KEY COMPANIES

8.1. Celprogen
8.2. Ritter Pharmaceuticals
8.3. Eurofarma Laboratorios S.A.

9. LACTOSE INTOLERANCE KEY PRODUCTS

9.1. CEP 801
9.2. RP G28
9.3. Lactase Oral Tablets

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. LACTOSE INTOLERANCE - UNMET NEEDS

12. LACTOSE INTOLERANCE - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Lactose Intolerance Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Lactose Intolerance Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Lactose Intolerance companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Lactose Intolerance Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

Celprogen
Ritter Pharmaceuticals
Pro Farma
Ritter Pharmaceuticals, Inc.
VenterPharma
Eurofarma Laboratorios S.A.


More Publications